Physician profile
Chen H Lin
NPI 1881960573
$18,577.64
in general payments reported to CMS, 2019-2025
28 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $142 · 2021: $446 · 2022: $2,443 · 2023: $1,313 · 2024: $1,569 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,628 · Food and Beverage: $4,061 · Travel and Lodging: $1,139 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,628.00 |
| Food and Beverage | $4,060.62 |
| Travel and Lodging | $1,138.74 |
| Education | $238.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $9,135.18 | 2025 | Andembry, Hizentra |
| Genzyme Corporation | $2,852.93 | 2019-2025 | |
| Blueprint Medicines Corporation | $2,569.64 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $555.39 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals LP | $470.54 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $453.10 | 2019-2025 | Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $373.26 | 2022-2025 | Dupixent |
| Pharming Healthcare, INC. | $357.97 | 2021-2025 | Ruconest |
| Sanofi Pasteur INC. | $286.44 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $276.10 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $184.66 | 2025 | |
| Octapharma USA, INC. | $155.97 | 2021-2022 | |
| Grifols USA, LLC | $134.14 | 2019-2025 | Xembify, Gamunex-C |
| Biocryst US Sales Co., LLC | $128.68 | 2021-2024 | Orladeyo |
| Alk-Abello, INC | $109.98 | 2020-2023 | Grastek, Odactra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $72.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $66.21 | 2024 | Ultomiris |
| Amgen INC. | $64.97 | 2024 | Actimmune |
| Gc Biopharma USA, INC. | $56.99 | 2025 | Alyglo |
| Fresenius Kabi USA, LLC | $52.50 | 2024-2025 | Stimufend, Tyenne |
| Lilly USA, LLC | $48.07 | 2025 | Ebglyss |
| Biocryst Pharmaceuticals, INC. | $44.58 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $34.87 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $25.78 | 2025 | Nemluvio |
| Abbott Laboratories | $24.93 | 2024 | Proclaim |
| Ionis Pharmaceuticals, INC. | $16.25 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Circassia INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.